Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF"

Affiliations

¹ From Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); and Duke Clinical Research Institute, Durham, NC (C.B.F., J.P.P., M.R.P.).

Comment

Christopher B Fordyce et al. Circulation. 2016.

. 2016 Nov 29;134(22):e532-e533.

doi: 10.1161/CIRCULATIONAHA.116.025258.

¹ From Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); and Duke Clinical Research Institute, Durham, NC (C.B.F., J.P.P., M.R.P.).

No abstract available

Comment on

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR; ROCKET AF Steering Committee and Investigators. Fordyce CB, et al. Circulation. 2016 Jul 5;134(1):37-47. doi: 10.1161/CIRCULATIONAHA.116.021890. Circulation. 2016. PMID: 27358435 Clinical Trial.
Letter by Escobar et al Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF".
Escobar C, Barrios V, Gorriz JL. Escobar C, et al. Circulation. 2016 Nov 29;134(22):e530-e531. doi: 10.1161/CIRCULATIONAHA.116.024514. Circulation. 2016. PMID: 27895027 No abstract available.